相关实验视频
Updated: Jun 29, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
被动心室约束可以防止左心室重塑过程中的跨壁剪切应变进展
Allen Cheng1, Tom C Nguyen, Marcin Malinowski
1Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, California 94305-5247, USA.
Circulation
|July 6, 2006
概括
在心肌梗塞 (MI) 后,Acorn心脏支持装置 (CSD) 防止左心室 (LV) 的不良重塑. 中证证券减轻剪切应变异常,防止LV扩张和减少墙壁应力.
科学领域:
- 心血管研究研究心血管研究
- 生物医学工程 生物医学工程
- 心脏机械学 心脏机械学
背景情况:
- 被动心室约束减少左心室 (LV) 壁应力和心肌张力,这是LV重塑的关键因素.
- 改变的壁应变可以触发亡,细胞外矩阵破坏和不良的LV扩张.
- 在此之前,Acorn心脏支装置 (CSD) 对区域横向LV壁菌株的影响是未知的.
研究的目的:
- 调查Acorn心脏支装置 (CSD) 在肌肉梗塞 (MI) 后对区域性横向LV壁菌株的影响.
- 评估CSD在预防不良LV重塑和心脏力学变化的有效性.
主要方法:
- 33只羊接受了手术,将放射性不透明的珠套插入LV壁,以测量4D标记器动态.
- 在18只羊中诱导了心肌梗塞 (MI);8只接受了CSD (MI+CSD),10只没有 (MI).
- 双飞机视频光学跟踪标记器动态,分析LV体积,球状度指数和心肌缩菌株在MI后1周和8周.
主要成果:
- 与Sham.相比,MI导致LV扩张,球形度指数降低,以及前侧壁的纵向-辐射剪切应变增加.
- 在MI+CSD羊中植入CSD可以防止这些剪切应变异常.
- 中央证券交易所尽量减少了 LV 末端透析体积增加,并增加了 LV 球状度指数.
结论:
- 预防性CSD有效地预防了心脏病发作引起的剪切应变进展,无论是邻近心脏病发作区域还是远离心脏病发作区域.
- 中心医疗中心证明,它有能力防止心脏病后的 LV 扩张和球化.
- 通过减轻剪切应变异常,CSD可以中断LV重塑的积极反循环,并减少不良心脏重塑的触发因素.
相关概念视频
Chambers of the Heart
The human heart is a complex organ made up of four chambers: the right and left atria and the right and left ventricles. These internal chambers are separated by partitions known as the interatrial and interventricular septa. The exterior of the heart features a groove known as the coronary sulcus that demarcates the atria from the ventricles, while the anterior and posterior interventricular sulci distinguish between the two ventricles.
Deoxygenated blood from the body is received in the right...
Deoxygenated blood from the body is received in the right...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

